US-based pharmaceutical giant Eli Lilly has introduced its Mounjaro KwikPen in India, marking a significant advancement in the management of Type 2 diabetes and obesity. The pre-filled, single-use device is designed for once-weekly administration, offering patients a more convenient and user-friendly treatment option.
Mounjaro KwikPen is available in six dose strengths, with prices starting at ₹14,000 for the 2.5mg variant and going up to ₹27,500 for the higher 12.5mg and 15mg doses. Winselow Tucker, President and General Manager of Lilly India, said the launch will enable healthcare professionals to create more personalized and effective treatment plans, aligning therapy with individual patient needs.
The medication is the first and only dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist, offering a unique mechanism of action. It is indicated as an adjunct to diet and exercise for adults with Type 2 diabetes, as well as for chronic weight management in adults with obesity or overweight who have at least one weight-related comorbidity. By regulating appetite, Mounjaro helps reduce body weight and fat mass, supporting broader metabolic health improvements.
Eli Lilly has emphasized that Mounjaro is strictly a prescription-only medicine and should be used solely under the supervision of a qualified healthcare professional. The company cautioned against its use for cosmetic purposes, noting that it is not approved solely for weight loss. Patients are advised to consult their doctor to determine whether Mounjaro is appropriate for their condition and overall health goals.
With its innovative delivery system and multi-mechanism approach, the launch of Mounjaro KwikPen represents a notable step forward in enhancing treatment accessibility and outcomes for patients in India managing Type 2 diabetes and obesity.